Member access

4-Traders Homepage  >  Shares  >  Copenhagen Stock Exchange  >  Novozymes A/S       DK0060336014

End-of-day quote. End-of-day quote Copenhagen Stock Exchange - 05/24
204 DKK   +1.34%
4d agoDJNovo Buys Xellia Pharmaceuticals for $700 Million
04/30 NOVOZYMES A/S: Updated Financial calendar 2013
04/22NOVOZYMES A/S: quaterly earnings release
SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 

Novozymes A/S : Share buyback program no. 17, 2012

05/16/2012| 04:39am US/Eastern
Recommend:
0

On January 20, 2012, Novozymes initiated a share buyback program in accordance with the provisions of European Commission Regulation no. 2273/2003 of December 22, 2003, also referred to as the Safe Harbour Regulation.

16. May 2012

Page Content

Under the program Novozymes will buy back B shares for an amount of up to DKK 1,000 million in the period from January 20, 2012, to December 31, 2012.

The following transactions have been made under the program:

Number of shares

Average
purchase price

Transaction

value, DKK

Accumulated, last announcement

2,228,361

356,019,429

May 11, 2012

27,355

150.45

4,115,494

May 14, 2012

20,670

149.55

3,091,144

May 15, 2012

36,500

150.58

5,496,084

Accumulated

under the program

2,312,886

368,722,151

Transactions related to Novozymes' incentive programs have resulted in a net sale by Novozymes of 4,895 B shares in the period from May 11, to May 15, 2012. The shares related to these transactions were not part of the Safe Harbour share buyback program.

With the transactions stated above, Novozymes owns a total of 10,302,380 treasury shares, corresponding to 3.2% of the share capital. The total amount of shares in the company is 325,000,000 including treasury shares.

Contact persons:

Press and media:

Investor relations:

René Tronborg (Europe)

Tel. (direct): +45 4446 2274

Tel. (mobile): +45 3077 2274

Paige Donnelly (USA)

Tel. (direct): +1 919 494 3209

Tel. (mobile): +1 919 218 4501

Martin Riise

Tel. (direct): +45 4446 0738

Tel. (mobile): +45 3077 0738

Thomas Bomhoff (USA)

Tel. (direct): +1 919 494 3483

Tel. (mobile): +1 919 649 2565

distributed by
Recommend :
0
Partner Area
React to this article
 
Latest news on NOVOZYMES A/S
4d agoDJNovo Buys Xellia Pharmaceuticals for $700 Million
04/30 NOVOZYMES A/S: Updated Financial calendar 2013
04/22NOVOZYMES A/S: quaterly earnings release
04/05 NOVOZYMES A/S: Reduction of share capital
04/01 NOVOZYMES A/S: Novozymes' new CEO takes office
03/01 NOVOZYMES A/S: Management trading no. 9, 2013
03/01 NOVOZYMES A/S: ex-dividend day for annual dividend
02/28 NOVOZYMES A/S: Novozymes A S Annual Shareholders Meeting 2013
02/26 NOVOZYMES A/S: Friendly Fungus Has Killer Instinct for Agricultural Pests
02/22 NOVOZYMES A/S: Acquisition of the enzymes business of Iogen Corporation complet..
Advertisement
Chart
Duration : Period :
Novozymes A/S Technical Analysis Chart | DK0060336014 | 4-Traders
Income Statement Evolution
Novozymes A_S : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.